Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News BioDelivery Sciences International Inc. BDSI

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

Recent & Breaking News (NDAQ:BDSI)

BioDelivery Sciences Announces the Launch of BELBUCA(TM) (Buprenorphine) Buccal Film by Endo Pharmaceuticals for Chronic Pain Management

PR Newswire February 22, 2016

Endo Announces Launch Of BELBUCA(TM) (Buprenorphine) Buccal Film For Chronic Pain Management

Canada NewsWire February 22, 2016

BioDelivery Sciences to Webcast Analyst & Investor Day on February 25th

PR Newswire February 18, 2016

BioDelivery Sciences to Host Analyst and Investor Day on February 25th in New York City

PR Newswire January 25, 2016

BioDelivery Sciences Provides Pipeline Update

PR Newswire December 18, 2015

BioDelivery Sciences Announces Organizational Changes

PR Newswire December 16, 2015

BioDelivery Sciences Hires Joseph M. Lockhart as Vice President of Manufacturing and Supply Chain

PR Newswire December 3, 2015

BioDelivery Sciences to Present at the 27th Annual Piper Jaffray Healthcare Conference

PR Newswire November 24, 2015

Where Opportunity is Found - Research on Applied Genetic Technologies, BioDelivery Sciences, Applied Optoelectronics and Five9

Accesswire November 18, 2015

BioDelivery Sciences to Present at the Jefferies 2015 Global Healthcare Conference

PR Newswire November 11, 2015

BioDelivery Sciences Provides Corporate Update and Reports Third Quarter 2015 Financial Results

PR Newswire November 9, 2015

BioDelivery Sciences to Host Conference Call and Webcast of Third Quarter 2015 Results on Monday, November 9

PR Newswire November 2, 2015

FDA Approval of BELBUCA(TM) (CIII) (Buprenorphine HCl) Buccal Film for Chronic Pain Triggers Milestone Payment of $50 Million to BioDelivery Sciences from Partner Endo Pharmaceuticals

PR Newswire October 26, 2015

U.S. FDA Approves BELBUCA(TM) (buprenorphine) Buccal Film for Chronic Pain Management

Canada NewsWire October 26, 2015

BioDelivery Sciences Announces FDA Approval of Change in BUNAVAIL® Product Specification Allowing for Immediate Release of Product

PR Newswire October 15, 2015

BioDelivery Sciences Announces Short-Term Supply Constraints for BUNAVAIL®

PR Newswire October 14, 2015

Healthcare Sector Stocks under Review - Celldex Therapeutics, Alexion Pharmaceuticals, Advaxis, BioDelivery Sciences and Cytori Therapeutics

PR Newswire September 29, 2015

LifeSci Capital Initiates Coverage of BioDelivery Sciences

Accesswire September 24, 2015

In a Move by the U.S. Department of Health and Human Services - Patient Limit on Access to Opioid Dependence Treatments to be Expanded

PR Newswire September 18, 2015

BioDelivery Sciences to Present at the 6th Annual Credit Suisse Small & Mid Cap Conference and the Ladenburg Thalmann 2015 Healthcare Conference

PR Newswire September 10, 2015